Branded as Kisunla by drugmaker Eli Lilly, donanemab's approval follows years of setbacks and delays in getting the ...

The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of ...

Eli Lilly's new drug, donanemab, targets amyloid proteins and slows cognitive decline more than others in its class.

For people newly diagnosed with early-stage Alzheimer’s disease, donanemab and lecanemab offer hope by slowing cognitive ...

Eli Lilly’s donanemab—to be sold under the brand name Kisunla—received regulatory approval as a monthly injection after an 18 ...

The FDA has approved a new medication for people with Alzheimer’s disease. Eli Lilly’s Kisunla (donanemab) is a once-monthly ...

The drug contains an antibody that aims to slow the progression of the incurable Alzheimer’s disease. It operates by ...

Donanemab-azbt is the first and only amyloid plaque-targeting therapy approved for adults with early symptomatic Alzheimer ...

The drug donanemab (also known as Kisunla™) has been approved by the US Food and Drug Administration (FDA) for the treatment ...

The Food and Drug Administration approved a new Alzheimer's treatment called donanemab on Tuesday, clearing the way for the third addition to a new class of drugs aimed at slowing the brain's ...

The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease. Donanemab, made by ...